A preparation method for a liposome having the ability to stably encapsulate an active ingredient is provided. The preparation method includes providing a mixture and homogenizing the mixture at 300 bar-400 bar to form a liposome suspension. The mixture includes 0.1 wt % of lecithin, 2 wt %-5 wt % of Arabic gum and 63.9125 wt %-97.9 wt % of a solvent. The liposome suspension includes a plurality of liposomes.

A method of manufacturing a suspension of gas-filled microvesicles by reconstituting a freeze-dried product and a suspension obtained according to said method, where the freeze-dried product has been subjected to a thermal treatment

Disclosed herein are pharmaceutical formulations of aprepitant suitable for parenteral administration including intravenous administration. The pharmaceutical formulations are stable and ready-to-use liposomes for the treatment of emesis and are particularly useful for treatment of chemotherapy or surgery-induced nausea and vomiting. Methods of preparation of the aprepitant formulations are also provided.

Some embodiments pertain to nanoparticle-based compositions and their use in methods for the delivery of CBD to subjects. In some embodiments, the compositions are stable for prolonged periods of time and provide enhanced bioavailability.

Nanostructures for the systemic delivery of nucleic acids, such as RNA, are provided herein. The nanostructures include templated lipoprotein nanoparticles (TLPs) composed of a core decorated with proteins, a lipid bilayer and hydrophobic molecules that self-assemble with nucleic acids, such as RNA. The nanostructures are useful for research, therapeutic and diagnostic applications.

The present disclosure provides inventive methods and formulations for immunosuppressive therapy for dry eye and other related immune mediated eye diseases. The formulations can comprise one or more immunomodulatory drugs such as parenterally administered liposome encapsulated rapamycin and topically administered tacrolimus. Immunomodulatory drugs herein can be formulated and administered to address the causes and/or reduce the symptoms of dry eye and/or other related immune mediated diseases of the eye.

Provided herein are improved methods for preparing phospholipid formulations including phospholipid UCA formulations.

The present invention relates in a first aspect to a method of coating surfaces of substrates with a lattice-like structure. In particular, the present invention relates to an in vitro method of coating surfaces by binding of epsin or a fragment thereof on the surface and, thereafter, binding of a compound forming the lattice like structure, in particular, binding of the clathrin heavy chain, to the epsin bound on the surface, thus, obtaining a coated substrate having a lattice like structure on the surface. In another aspect, the present invention relates to an in vitro method of producing nanometer-sized liposomes having a clathrin structure on its surface. In addition, substrates, like elements or devices, with coated surfaces having a lattice-like structure on the surface are provided obtainable by a method according to the present invention.

A dietary supplement composition has a dispersion including a plurality of liposomal vesicles. The dietary supplement composition includes an active ingredient including one or more hydrophobic nutrient, such as cannabinoid or cannabinoid compound (cannabinoid), and phospholipid contained in the liposomal vesicles. The cannabinoid, which may be combined with cyclodextrin, is incorporated within the liposomal vesicles. The dietary supplement composition may further include one or more of rice bran extract, mannitol and trehalose. A method of preparing such dietary supplement composition includes generating a cannabinoid phase, generating an phospholipid phase, adding the cannabinoid phase and the phospholipid phase in vessel; performing a homogenizing step by mixing the cannabinoid phase and the phospholipid phase so as to form a cannabinoid-phospholipid composition having a plurality of liposomal vesicles having the cannabinoid incorporated therein, wherein the concentration of cannabinoid in the cannabinoid-phospholipid composition is about 10 to 25 mass %.

The embodiments herein provide a nano-carrier system for delivering a long-acting injectable drug of morphine and a method of synthesising the same. The morphine entrapped nanoparticles are prepared using a lipid/phospholipid core which is coated by a polymer. The lipid and phospholipid are dissolved in organic solvent. This solution is transferred into an aqueous phase consisting of distilled water or a buffer. A solution of polymer is added drop wise. The drug entrapped nanoparticle formation is achieved by diffusion of the organic solvent within the aqueous solvent to obtain the nanoparticles. The drug gets entrapped within the nanoparticles via the anti-solvency effect of the aqueous matrix. The resulting drug nanocarriers are capable of releasing the drug in a slow rate upon injection. The synthesized drug carrying nanoparticles are cryopreserved stored for future administration. For better storage, the nanodispersion is dried to form a powder.